CIQ|CAS 486427-17-2|DC Chemicals

Cas No.:	486427-17-2
Chemical Name:	(3-chlorophenyl){6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-3,4-d Ihydro-2(1h)-isoquinolinyl}methanone
Synonyms:	(3-Chlorophenyl){6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-3,4-d ihydro-2(1H)-isoquinolinyl}methanone;CIQ;(3-Chlorophenyl)[3,4-dihydro-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-2(1H)-isoquinolinyl]-methanone
SMILES:	O=C(C1=CC=CC(Cl)=C1)N2C(COC3=CC=C(OC)C=C3)C4=C(C=C(OC)C(OC)=C4)CC2
Formula:	C₂₆H₂₆NO₅Cl
M.Wt:	467.94134
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit. IC50 value: 2.7 μM (EC50, for NR2C) and 2.8 μM (EC50, NR2D)Target: NMDA receptorCIQ increases channel opening frequency of recombinant NR2Cor NR2D containing receptors by two-fold (EC50 = 2.7 and 2.8 μM, respectively), with no effect on NR2A or NR2B subtypes. CIQ does not alter the EC50 values for glutamate or glycine on channel opening. CIQ increases channel opening efficiency and enhances NMDA receptor responses. CIQ reduces associated behaviours in schizophrenia models and potentially enhances dopamine release in Parkinson's disease models.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC8824	Traxoprodil	Traxoprodil is an NMDA ε 2 (NR2B) antagonist that has been studied as an alternative to serotonin selective reuptake inhibitors.
DC7863	Talampanel (GYKI 53773)	Talampanel is a novel anticonvulsant that acts as an allosteric inhibitor of the AMPA receptor.
DC8175	Rapastinel(GLYX-13)	Rapastinel(GLYX-13) is a NMDA receptor partial agonist that acts at the glycine site.
DC8307	QNZ46	QNZ is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively).
DC7226	Perampanel(E2007）	Perampanel(E2007; ER 155055-90) is a selective noncompetitive AMPA-type glutamate receptor antagonist which has demonstrated anticonvulsant activity in experimental seizure models and antiepileptic activity in clinical trials.
DC7989	PEPA	PEPA is an allosteric modulator of AMPA receptors; binds to the GluA2o and GluA3o LBDs and can be utilized as an indicator of AMPA receptor heterogeneity.
DC11382	NYX-2925	NYX-2925 is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory.
DC7576	NVP-AAM077	NVP-AAM077 is a potent antagonist for NMDA receptors.
DC11406	NBQX	NBQX is a potent aminomethylphosphonic acid receptor (AMPAR) antagonist with an IC50 of 0.7 ± 0.1 μM.
DC7194	MDL 29951	MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo.